Clinical Pharmacology (CP)
临床药理学(CP)
基本信息
- 批准号:10311226
- 负责人:
- 金额:$ 10.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-08-04 至 2024-11-30
- 项目状态:已结题
- 来源:
- 关键词:Biological AssayBudgetsCancer Center Support GrantCellsClinicalClinical Cancer CenterClinical OncologyClinical PharmacologyClinical ResearchConcentration measurementConsultationsDNAData AnalysesDevelopmentDrug CombinationsDrug KineticsEpidemiologyFacultyFluorescenceFundingHigh Pressure Liquid ChromatographyInvestigationInvestigational DrugsInvestigational New Drug ApplicationInvestigational TherapiesMalignant NeoplasmsMolecularNorris Cotton Cancer CenterOncologyPerformancePeripheral Blood Mononuclear CellPharmaceutical PreparationsPharmaceutical ServicesPharmacistsPharmacodynamicsPharmacologyPharmacology Shared ResourcePharmacy facilityPhasePlasmaPre-Clinical ModelProtocols documentationResearchResearch AssistantResearch DesignResearch MethodologyResearch PersonnelSalivaSamplingServicesSiteTestingTherapeuticTherapeutic StudiesTumor TissueUrinecostdata modelingdesigndetection methodepidemiology studyin vivoliquid chromatography mass spectrometrymembernoveloperationpharmacodynamic modelpharmacokinetics and pharmacodynamicspre-clinicalpreclinical studyprogramstranslational therapeuticsultraviolet
项目摘要
Project Summary/Abstract: Clinical Pharmacology
The Clinical Pharmacology (CP) Shared Resource is in its 24th year of operation and supports Norris Cotton
Cancer Center (NCCC) investigators in the design, performance, data analysis, and interpretation of
pharmacology objectives in preclinical (in vivo and ex vivo), clinical and epidemiological studies at the lowest
cost and highest value possible. The major CP services are in four domains: (1a) Development of novel
analyte assays (when such assays are only available as research methods) increasingly using either liquid-
chromatography mass spectrometry (LC-MS/MS) or high performance liquid chromatography (HPLC) with
ultra-violet and/or fluorescence detection methods; (1b) Performance of analyte-concentration measurements
in biospecimens from preclinical and clinical oncology studies using these validated bioanalytical assays; (2a)
Expert consultation regarding study design and pharmacokinetic (PK) and pharmacodynamic (PD) hypothesis-
development and testing in preclinical and clinical cancer studies; (2b) PK and PD data analysis and PK-PD
modeling from pre-clinical and clinical studies; (3) Central processing for biospecimens (e.g., cells, tumor
tissue, plasma, saliva, urine, DNA) obtained as part of approved clinical and epidemiological protocols;
services that include: sample logging, processing (including processing peripheral blood mononuclear cells),
aliquoting, storage and sample distribution when necessary; and (4) Research pharmacy services for cancer
therapeutic clinical studies with both commercially available drugs and drugs under an investigational new drug
application. CP is directed by Dr. Lionel D. Lewis, who has established expertise in the clinical performance of
PK and PD for early phase clinical studies of investigational oncology drug or drug/drug combinations. Other
staff includes a junior faculty pharmacologist with bioanalytical and molecular pharmacology expertise, a
research assistant-lab manager with expanding bioanalytical and biospecimen stewardship expertise, and a
research pharmacist with expertise in oncologic and investigational drug pharmacy. During the period 1/1/15 to
11/30/18, 15 NCCC Members from all 4 NCCC Programs utilized the CP Shared Resource, 9 of whom are
current Members in 3 Programs (CPS [2], CBT [6], and ICI [1]). NCCC Funded Member Use represented 93%
of Total Use (42 Projects), and we are requesting 78% of the CP Total Operating Budget from CCSG support.
项目摘要/摘要:临床药理学
临床药理学(CP)共享资源已运行24年,支持Norris Cotton
癌症中心(NCCC)的研究人员参与设计、性能、数据分析和解释
临床前(体内和体外)、临床和流行病学研究的药理学目标最低
成本和尽可能高的价值。主要的CP业务有四个领域:(1)开发新的
分析物分析(当这种分析只作为研究方法可用时)越来越多地使用液体-
色谱质谱联用(LC-MS/MS)或高效液相色谱(HPLC)
紫外线和/或荧光检测方法;(1b)分析物浓度测量的性能
来自临床前和临床肿瘤学研究的生物样本,使用这些经过验证的生物分析方法;(2a)
关于研究设计和药代动力学(PK)和药效学(PD)假说的专家咨询-
临床前和临床癌症研究的开发和测试;(2b)PK和Pd数据分析和PK-Pd
来自临床前和临床研究的建模;(3)生物样品(例如细胞、肿瘤)的中央处理
组织、血浆、唾液、尿液、DNA),作为批准的临床和流行病学方案的一部分获得;
服务内容包括:样品采集、加工(包括外周血单核细胞加工)、
(4)癌症研究药房服务
市售药物和研究用新药的临床治疗研究
申请。CP由莱昂内尔·D·刘易斯博士执导,他在临床表现方面拥有丰富的专业知识
PK和PD用于研究肿瘤学药物或药物/药物组合的早期临床研究。其他
工作人员包括一名具有生物分析和分子药理学专业知识的初级学院药剂师,
研究助理-实验室经理,具有不断扩展的生物分析和生物显微镜管理专业知识,以及
具有肿瘤学和研究药物药剂学专业知识的研究药剂师。在1/1/15至
11/30/18,来自所有4个NCCC计划的15个NCCC成员使用了CP共享资源,其中9个是
目前是3个计划(CPS[2]、CBT[6]和ICI[1])的成员。NCCC资助的会员使用率为93%
占总使用量的78%(42个项目),我们要求CCSG支持部门提供总运营预算的78%。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LIONEL David LEWIS其他文献
LIONEL David LEWIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LIONEL David LEWIS', 18)}}的其他基金
7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors
7HP349,一种整合素激活剂,用于治疗抗 PD-1 耐药实体瘤患者
- 批准号:
10761171 - 财政年份:2023
- 资助金额:
$ 10.99万 - 项目类别:
Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors
开发 7HP349,一种口服整合素激活剂,可增强对免疫检查点抑制剂的治疗反应
- 批准号:
10261525 - 财政年份:2020
- 资助金额:
$ 10.99万 - 项目类别:
Toxicology, Pathology and Biodistribution Core (TPB Core)
毒理学、病理学和生物分布核心(TPB 核心)
- 批准号:
7982610 - 财政年份:2010
- 资助金额:
$ 10.99万 - 项目类别:
Protocol Review and Monitoring System (PRMS)
方案审查和监控系统 (PRMS)
- 批准号:
10554303 - 财政年份:1997
- 资助金额:
$ 10.99万 - 项目类别:
Protocol Review and Monitoring System (PRMS)
方案审查和监控系统 (PRMS)
- 批准号:
10311241 - 财政年份:1997
- 资助金额:
$ 10.99万 - 项目类别:
相似海外基金
Can megafauna shift the carbon and surface radiation budgets of the Arctic?
巨型动物群能否改变北极的碳和地表辐射预算?
- 批准号:
NE/W00089X/2 - 财政年份:2024
- 资助金额:
$ 10.99万 - 项目类别:
Research Grant
Resilience of pollinators in a changing world: impact of developmental environment on metabolism and energetic budgets in social and solitary bees
不断变化的世界中授粉媒介的复原力:发育环境对群居和独居蜜蜂新陈代谢和能量预算的影响
- 批准号:
BB/X016641/1 - 财政年份:2024
- 资助金额:
$ 10.99万 - 项目类别:
Research Grant
An innovative EDI data, insights & peer benchmarking platform enabling global business leaders to build data-led EDI strategies, plans and budgets.
创新的 EDI 数据、见解
- 批准号:
10100319 - 财政年份:2024
- 资助金额:
$ 10.99万 - 项目类别:
Collaborative R&D
Nutrient budgets as a tool for minimizing nitrogen and phosphorus losses from agricultural fields
养分预算作为最大限度减少农田氮磷损失的工具
- 批准号:
574867-2022 - 财政年份:2022
- 资助金额:
$ 10.99万 - 项目类别:
University Undergraduate Student Research Awards
Collaborative Research: ORCC: The role of bioenergetic budgets in defining elevation limits and modeling geographic ranges of species
合作研究:ORCC:生物能预算在定义海拔限制和建模物种地理范围中的作用
- 批准号:
2222475 - 财政年份:2022
- 资助金额:
$ 10.99万 - 项目类别:
Standard Grant
Collaborative Research: ORCC: The role of bioenergetic budgets in defining elevation limits and modeling geographic ranges of species
合作研究:ORCC:生物能预算在定义海拔限制和建模物种地理范围中的作用
- 批准号:
2222476 - 财政年份:2022
- 资助金额:
$ 10.99万 - 项目类别:
Continuing Grant
CNS Core: Small: Budgets, Budgets Everywhere: A Necessity for Safe Real-Time on Multicore
CNS 核心:小:预算,预算无处不在:多核安全实时的必要性
- 批准号:
2151829 - 财政年份:2022
- 资助金额:
$ 10.99万 - 项目类别:
Standard Grant
Sea-ice Snow Microbial Communities’ Impact on Antarctic Bromocarbon Budgets and Processes
海冰雪微生物群落对南极溴碳预算和过程的影响
- 批准号:
2031121 - 财政年份:2022
- 资助金额:
$ 10.99万 - 项目类别:
Standard Grant
Breathing streams: integrating aquatic emissions into carbon budgets
呼吸流:将水生排放纳入碳预算
- 批准号:
DE220100852 - 财政年份:2022
- 资助金额:
$ 10.99万 - 项目类别:
Discovery Early Career Researcher Award
Can megafauna shift the carbon and surface radiation budgets of the Arctic?
巨型动物群能否改变北极的碳和地表辐射预算?
- 批准号:
NE/W00089X/1 - 财政年份:2022
- 资助金额:
$ 10.99万 - 项目类别:
Research Grant